Clinical Trial Update: A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing a single 1.5 mL dose of brodalumab to a two-dose regimen (1.0 mL + 0.5 mL) in patients with psoriasis; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2017-06-20